Course of disease and risk factors for hospitalization in outpatients with a SARS-CoV-2 infection

We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Scientific reports Ročník 12; číslo 1; s. 7249 - 12
Hlavní autori: Schäfer, Eik, Scheer, Christian, Saljé, Karen, Fritz, Anja, Kohlmann, Thomas, Hübner, Nils-Olaf, Napp, Matthias, Fiedler-Lacombe, Lizon, Stahl, Dana, Rauch, Bernhard, Nauck, Matthias, Völker, Uwe, Felix, Stephan, Lucchese, Guglielmo, Flöel, Agnes, Engeli, Stefan, Hoffmann, Wolfgang, Hahnenkamp, Klaus, Tzvetkov, Mladen V.
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: London Nature Publishing Group UK 04.05.2022
Nature Publishing Group
Nature Portfolio
Predmet:
692/308
692/499
692/699
692/700
Ageusia - epidemiology
Ageusia - etiology
Anosmia
Anosmia - epidemiology
Anosmia - etiology
Arthralgia
Chronic obstructive pulmonary disease
Coronary artery disease
Cough
Cough - diagnosis
COVID-19
COVID-19 - complications
COVID-19 - epidemiology
Diabetes mellitus
Differential diagnosis
Dyspnea
Dyspnea - etiology
Fever
Health risks
Heart diseases
Hospitalization
Humanities and Social Sciences
Humans
Infections
Middle Aged
multidisciplinary
Myalgia
Nausea
Olfaction
Olfaction disorders
Outpatients
Respiration
Risk Factors
SARS-CoV-2
Science
Science (multidisciplinary)
Severe acute respiratory syndrome coronavirus 2
Taste disorders
Vomiting
ISSN:2045-2322, 2045-2322
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:We analyzed symptoms and comorbidities as predictors of hospitalization in 710 outpatients in North-East Germany with PCR-confirmed SARS-CoV-2 infection. During the first 3 days of infection, commonly reported symptoms were fatigue (71.8%), arthralgia/myalgia (56.8%), headache (55.1%), and dry cough (51.8%). Loss of smell (anosmia), loss of taste (ageusia), dyspnea, and productive cough were reported with an onset of 4 days. Anosmia or ageusia were reported by only 18% of the participants at day one, but up to 49% between days 7 and 9. Not all participants who reported ageusia also reported anosmia. Individuals suffering from ageusia without anosmia were at highest risk of hospitalization (OR 6.8, 95% CI 2.5–18.1). They also experienced more commonly dyspnea and nausea (OR of 3.0, 2.9, respectively) suggesting pathophysiological connections between these symptoms. Other symptoms significantly associated with increased risk of hospitalization were dyspnea, vomiting, and fever. Among basic parameters and comorbidities, age > 60 years, COPD, prior stroke, diabetes, kidney and cardiac diseases were also associated with increased risk of hospitalization. In conclusion, due to the delayed onset, ageusia and anosmia may be of limited use in differential diagnosis of SARS-CoV-2. However, differentiation between ageusia and anosmia may be useful for evaluating risk for hospitalization.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-022-11103-0